Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab.

Voors-Pette C, Lebozec K, Dogterom P, Jullien L, Billiald P, Ferlan P, Renaud L, Favre-Bulle O, Avenard G, Machacek M, Plétan Y, Jandrot-Perrus M.

Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964. doi: 10.1161/ATVBAHA.118.312314.

PMID:
31017822
2.

Biomolecular engineering of antidehydroepiandrosterone antibodies: a new perspective in cancer diagnosis and treatment using single-chain antibody variable fragment.

Fogaça RL, Alvarenga LM, Woiski TD, Becker-Finco A, Teixeira KN, Silva SK, de Moraes RN, Noronha L, Noiray M, de Figueiredo BC, Billiald P, Moura J.

Nanomedicine (Lond). 2019 Mar;14(6):689-705. doi: 10.2217/nnm-2018-0230. Epub 2019 Jan 29.

PMID:
30691340
3.

Antibody Fragments Humanization: Beginning with the End in Mind.

Aubrey N, Billiald P.

Methods Mol Biol. 2019;1904:231-252. doi: 10.1007/978-1-4939-8958-4_10.

PMID:
30539473
4.

Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development.

Lebozec K, Jandrot-Perrus M, Avenard G, Favre-Bulle O, Billiald P.

N Biotechnol. 2018 Sep 25;44:31-40. doi: 10.1016/j.nbt.2018.04.006. Epub 2018 Apr 22.

PMID:
29689305
5.

Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks.

Lebozec K, Jandrot-Perrus M, Avenard G, Favre-Bulle O, Billiald P.

MAbs. 2017 Aug/Sep;9(6):945-958. doi: 10.1080/19420862.2017.1336592. Epub 2017 Jun 9.

6.

Generation of recombinant antibody fragments with toxin-neutralizing potential in loxoscelism.

Karim-Silva S, Moura Jd, Noiray M, Minozzo JC, Aubrey N, Alvarenga LM, Billiald P.

Immunol Lett. 2016 Aug;176:90-6. doi: 10.1016/j.imlet.2016.05.019. Epub 2016 Jun 7.

7.

Generation and characterization of monoclonal antibody against Advanced Glycation End Products in chronic kidney disease.

Finco AB, Machado-de-Ávila RA, Maciel R, De Moura J, Billiald P, Stinghen AEM, Alvarenga LM.

Biochem Biophys Rep. 2016 Mar 23;6:142-148. doi: 10.1016/j.bbrep.2016.03.011. eCollection 2016 Jul.

8.

Immunodetection of the "brown" spider (Loxosceles intermedia) dermonecrotoxin with an scFv-alkaline phosphatase fusion protein.

Jiacomini I, Silva SK, Aubrey N, Muzard J, Chavez-Olortegui C, De Moura J, Billiald P, Alvarenga LM.

Immunol Lett. 2016 May;173:1-6. doi: 10.1016/j.imlet.2016.03.001. Epub 2016 Mar 10.

9.

A method to confer Protein L binding ability to any antibody fragment.

Lakhrif Z, Pugnière M, Henriquet C, di Tommaso A, Dimier-Poisson I, Billiald P, Juste MO, Aubrey N.

MAbs. 2016;8(2):379-88. doi: 10.1080/19420862.2015.1116657. Epub 2015 Dec 18.

10.

Engineering venom's toxin-neutralizing antibody fragments and its therapeutic potential.

Alvarenga LM, Zahid M, di Tommaso A, Juste MO, Aubrey N, Billiald P, Muzard J.

Toxins (Basel). 2014 Aug 21;6(8):2541-67. doi: 10.3390/toxins6082541. Review.

11.

Colorimetric engineered immunoprobe for the detection and quantification of microcystins.

Alvarenga LM, Muzard J, Ledreux A, Bernard C, Billiald P.

J Immunol Methods. 2014 Apr;406:124-30. doi: 10.1016/j.jim.2014.02.014. Epub 2014 Mar 6.

PMID:
24607607
12.

Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies.

Fields C, O'Connell D, Xiao S, Lee GU, Billiald P, Muzard J.

Nat Protoc. 2013 Jun;8(6):1125-48. doi: 10.1038/nprot.2013.057. Epub 2013 May 16.

PMID:
23680984
13.

Diabody mixture providing full protection against experimental scorpion envenoming with crude Androctonus australis venom.

di Tommaso A, Juste MO, Martin-Eauclaire MF, Dimier-Poisson I, Billiald P, Aubrey N.

J Biol Chem. 2012 Apr 20;287(17):14149-56. doi: 10.1074/jbc.M112.348912. Epub 2012 Feb 28.

14.

Design and reshaping of an scFv directed against human platelet glycoprotein VI with diagnostic potential.

Zahid M, Loyau S, Bouabdelli M, Aubrey N, Jandrot-Perrus M, Billiald P.

Anal Biochem. 2011 Oct 15;417(2):274-82. doi: 10.1016/j.ab.2011.06.036. Epub 2011 Jul 2.

PMID:
21771576
15.

Will leaded young mallards take wing? Effects of a single lead shot ingestion on growth of juvenile game-farm Mallard ducks Anas platyrhynchos.

Plouzeau E, Guillard O, Pineau A, Billiald P, Berny P.

Sci Total Environ. 2011 May 15;409(12):2379-83. doi: 10.1016/j.scitotenv.2011.03.012. Epub 2011 Apr 7.

PMID:
21477844
16.

Design and humanization of a murine scFv that blocks human platelet glycoprotein VI in vitro.

Muzard J, Bouabdelli M, Zahid M, Ollivier V, Lacapère JJ, Jandrot-Perrus M, Billiald P.

FEBS J. 2009 Aug;276(15):4207-22. doi: 10.1111/j.1742-4658.2009.07129.x. Epub 2009 Jun 25.

17.

Non-invasive molecular imaging of fibrosis using a collagen-targeted peptidomimetic of the platelet collagen receptor glycoprotein VI.

Muzard J, Sarda-Mantel L, Loyau S, Meulemans A, Louedec L, Bantsimba-Malanda C, Hervatin F, Marchal-Somme J, Michel JB, Le Guludec D, Billiald P, Jandrot-Perrus M.

PLoS One. 2009;4(5):e5585. doi: 10.1371/journal.pone.0005585. Epub 2009 May 18.

18.

Grafting of protein L-binding activity onto recombinant antibody fragments.

Muzard J, Adi-Bessalem S, Juste M, Laraba-Djebari F, Aubrey N, Billiald P.

Anal Biochem. 2009 May 15;388(2):331-8. doi: 10.1016/j.ab.2009.02.035. Epub 2009 Mar 4.

PMID:
19268418
19.

[Antithrombotic recombinant antibodies].

Muzard J, Loyau S, Ajzenberg N, Billiald P, Jandrot-Perrus M.

J Soc Biol. 2006;200(4):365-75. Review. French.

PMID:
17652972
20.

[Recombinant antibodies: towards a new generation of antivenoms?].

Aubrey N, Muzard J, Juste M, Billiald P.

J Soc Biol. 2006;200(4):345-54. Review. French.

PMID:
17652970

Supplemental Content

Loading ...
Support Center